h. pylori

Rabeprazole Sulfide (Rabeprazole Related Compound E) is an antiulcer drug in the class of proton pump inhibitors.

Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug/mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

pNNP (Nitrophenylphosphate) can be used as a substrate for the PP2C assay. pNNP inhibits β-carbonic anhydrase and α-carbonate dehydrogenase, as well as H. pylori Helicobacter pylori. pNNP is a weakly active, tissue-nonspecific alkaline phosphatase modifier. pNNP has been shown to inhibit β-carbonic anhydrase and α-carbonate dehydrogenase.

HpFabZ Inhibitor 1 (compound 1) is a selective inhibitor of HpFabZ (H. pylori

Xinjiachalcone A is a natural product isolated from Glycyrrhiza inflata Batalin. Xinjiachalcone A shows both a low MIC and a strong bactericidal activity against H. pylori(MIC : 12.5 to 50 µM, seventeen H. pylori strains).

4-Hexen-3-one inhibits the growth of H. pylori in the ATCC 43526 strain and TDR strain. Additionally, this compound suppresses urease activity.

VPC162134 is an antibacterial agent that inhibits H. pylori, C. jejuni, MRSA, and S. epidermidis with minimum inhibitory concentrations (MIC) of 2.9, 17.5, 93.3, and 93.3 μM, respectively. Additionally, VPC162134 acts as an inhibitor of the enzyme pyruvate ferredoxin oxidoreductase (PFOR).

JAK05 exhibits inhibitory activity against Helicobacter pylori, effectively suppressing strains J63, J196, and J107, with a MIC of 3-5 µg mL. It shows affinity for binding to H+ K+-ATPase, COX-1 2, TNF-α, and PGE2, and possesses antioxidant and anti-inflammatory properties. In a rat model of ethanol-induced gastric ulcers, JAK05 demonstrates anti-ulcer activity.

BAS-118 is a benzamide derivative exhibiting antibacterial activity. For 100 randomly selected strains of Helicobacter pylori, its MIC50, MIC90, and MIC range were ≤0.003, 0.013, and ≤0.003-0.025 mg L, respectively. BAS-118 shows potential for research as an anti-H. pylori agent.

Urease-IN-20 (compound XBP2) is an inhibitor of Helicobacter pylori (H. pylori), with an IC50 of 0.14 μM for H. pylori inhibition. It effectively decreases apoptosis in GES-1 cells infected with H. pylori and reduces levels of ROS and γH2AX. Urease-IN-20 also demonstrates significant gastric mucosal protective effects, making it suitable for H. pylori research.

FR-193879 is an efficacious cephem derivative, it has extremely potent therapeutic efficacy against H. pylori.

Actinopyrone A is a pyrone isolated from S. pactum with diverse biological activities, showing selective and potent antimicrobial activity against H. pylori (MIC = 0.1 ng mL) and no activity against other Gram-negative bacteria including E. coli, K. pneumoniae, P. aeruginosa, and B. fragilis. It mildly inhibits the growth of Gram-positive bacteria and dermatophytes with MIC values ranging from <6.25 to 25 μg mL. Intravenous administration of actinopyrone A (30 μg kg) increases coronary blood flow in dogs by 196.2%.

cis-9,10-Methyleneoctadecanoic acid is a cyclopropane fatty acid found in bacteria and the digestive gland of P. globosa, forming a component of S. aureus cell membranes with levels that decrease upon treatment with carvacrol. Secreted by H. pylori, it enhances histamine- and dibutyryl cAMP-stimulated acid secretion in isolated guinea pig parietal cells and activates protein kinase C (PKC) in a calcium-dependent manner.

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].

1. 8-Gingerol has antioxidant activity. 2. 8-Gingerol has antimycobacterial activity. 3. 8-Gingerol could be used as an effective skin-whitening agent. 4. 8-Gingerol shows antipyretic and anti-inflammation characteristics. 5. 8-Gingerol seems to be effect

Antibacterialagent 233 (Compound 7c) demonstrates inhibitory activity against Helicobacter pylori, with a minimum inhibitory concentration (MIC) ranging from 0.4 to 1.6 μg mL. It inhibits jack bean urease with an IC50 of 0.27 μg mL, alters the permeability of the H. pylori cell membrane, and leads to the leakage of cellular contents. Antibacterialagent 233 shows metabolic stability in both whole blood and artificial gastric fluid. Additionally, it exhibits antitumor activity against U2OS in mice.

6,8-Diprenylorobol possesses weaker anti-H. pylori activity, it may be a useful chemopreventive agent for peptic ulcer or gastric cancer in H. pylori-infected individuals.

22-Dehydroclerosterol has antibacterial activity against against E. coli, S. aureus, and H. pylori.

9-Hydroxy-alpha-lapachone can highly inhibit the growth of H. pylori, it exhibits potent inhibitory activity against H. pylori Cystathionine gamma-synthase, with IC(50) values of 4.64 microM. It may have anti-inflammatory activity, it exhibits potent inhi

Dihydrolicoisoflavone A possesses weaker anti-H. pylori activity, it may be useful chemopreventive agents for peptic ulcer or gastric cancer in H. pylori-infected individuals.

Isojacareubin displays potent activity against H. pylori HP40 clinical isolate with MIC 23.9 uM, which is approximately two times greater than that of the standard drug amoxicillin. Isojacareubin is a potent inhibitor of protein kinase C (PKC), suppresses

The enzyme α-1,4-N-Acetylglucosaminyltransferase 4 (EC 2.4.1, A4GNT) catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans and inhibits the growth of Helicobacter pylori (H. pylori).